Combination therapy | Number of patients | Percentage of patients | N (%) male | N (%) female | Median age (IQR) (years) |
Hydroxychloroquine+lopinavir+ritonavir | 307 | 28.09% | 191 (62) | 116 (38) | 68 (57–77) |
Hydroxychloroquine+lopinavir/ritonavir+azithromycin | 302 | 27.63% | 181 (60) | 121(40) | 69 (57–77) |
Hydroxychloroquine+azithromycin | 266 | 24.34% | 130 (49) | 136 (51) | 75 (61–84) |
Azithromycin+lopinavir/ritonavir | 7 | 0.64% | 3 (43) | 4 (57) | 87 (76–91) |
Azithromycin | 104 | 9.52% | 52 (50) | 52 (50) | 87 (78–93) |
Hydroxychloroquine | 88 | 8.05% | 47 (53) | 41 (47) | 79 (64–83) |
Lopinavir/ritonavir | 19 | 1.74% | 12 (63) | 7 (37) | 75 (59–85) |
Total | 1093 | 100% | 616(56) | 477(44) | 75(59–80) |